## EMN: Eastman Chemical Company - XLB: Basic Materials

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 6.5% in lower entry zone (4.0-10.0%), top quartile (84th pct) cross-sectional ranking. Short-term MRS_5 (2.2%) confirms momentum alignment. Strong momentum (+7.0% 5-day acceleration). Outperforming sector by 3.6%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($59.97)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 6
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. RBC Raises Price Target on Eastman Chemical to $74 From $71, Keeps Outperform Rating**
- Source: marketscreener.com | 20251216T123421 | Bullish | Relevance: 100%
- RBC has increased its price target for Eastman Chemical (EMN) to $74, up from $71, while maintaining an "Outperform" rating on the stock. This adjustment reflects continued confidence in the company's performance. The company also recently announced an increase in its quarterly dividend to $0.84 per share.

**2. Assessing Eastman Chemical’s Valuation After Its 16th Straight Dividend Hike and New Cost-Cutting Goals**
- Source: Simply Wall Street | 20251213T180751 | Somewhat-Bullish | Relevance: 100%
- Eastman Chemical (EMN) has increased its dividend for the 16th consecutive year and announced new cost-cutting goals. Despite negative share price momentum over the past year, a recent rebound suggests stabilizing sentiment. The stock is currently trading at a discount to analyst targets, prompting a valuation debate regarding whether it presents a buying opportunity.

**3. Assessing Eastman Chemical’s Valuation After Its 16th Straight Dividend Hike and New Cost-Cutting Goals**
- Source: Simply Wall Street | 20251213T180745 | Somewhat-Bullish | Relevance: 100%
- Eastman Chemical (EMN) has increased its dividend for the 16th consecutive year and announced new cost-cutting goals. Despite negative shareholder returns over the past year, a recent rebound suggests stabilizing sentiment. The stock appears undervalued at $65.12 against a fair value of $72.76, prompting investors to consider if this represents a buying opportunity.

**4. Walnut Level Capital LLC Buys 47,946 Shares of Eastman Chemical Company $EMN**
- Source: MarketBeat | 20251214T134959 | Neutral | Relevance: 100%
- Walnut Level Capital LLC significantly increased its stake in Eastman Chemical (NYSE:EMN) by 111.2% in Q2, acquiring 47,946 additional shares to reach a total of 91,061 shares valued at approximately $6.80 million. This makes Eastman Chemical its 6th largest holding, representing about 3.7% of its portfolio. Concurrently, Eastman Chemical reported Q2 EPS of $1.14 due to revenues of $2.20 billion, missing analyst estimates, and announced an increase in its quarterly dividend to $0.84, resulting in an annualized yield of 5.1%.

**5. Eastman Chemical Company $EMN Stake Lessened by Atlantic Investment Management Inc.**
- Source: MarketBeat | 20251213T090745 | Neutral | Relevance: 100%
- Atlantic Investment Management Inc. significantly reduced its stake in Eastman Chemical Company ($EMN) by 46.5% in the second quarter, now holding 134,710 shares valued at approximately $10.06 million, making it their 7th largest holding. Despite this, other institutional investors have increased their positions. Eastman Chemical reported Q3 EPS of $1.14, missing analyst estimates, but increased its quarterly dividend to $0.84, offering a 5.1% yield.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 11 ($0.08M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 12.6% (-2.2%)
- Blackrock Inc.: 7.0% (+0.9%)
- State Street Corpora: 5.0% (+24.3%)
- Capital Research Glo: 3.7% (-1.0%)
- Dimensional Fund Adv: 3.5% (+14.4%)

### Key Risks

1. Valuation risk: PEG 3.9x with declining EPS estimates leaves no margin for error.
2. Long-term trend broken: trading 11.9% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +7.0% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 3.87 signals overvaluation risk, limited margin of safety. Forward P/E 10.3x attractive for 14% earnings growth. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $7.3B |
| Beta | 1.25 |
| 52W Range | $56.11 - $103.82 |
| Short Interest | 4.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.87 |
| Forward P/E | 10.3 |
| Current P/E | 11.7 |
| YoY Growth | 14.1% |
| EPS Direction | FALLING |

### Technicals

MRS_20 strengthening from -0.5% to 6.5% (+7.0% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 84th percentile. MRS_5 at 2.2% confirms short-term momentum alignment. AM_20 at 6.2% shows strong absolute momentum above own 20MA. Outperforming sector by 3.6pp, stock-specific strength. Below SMA200 (0.88x), long-term trend not supportive. MACD histogram positive (0.55), confirming momentum. RSI neutral at 57. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 6.52% (CS: 84) | Strong |
| RSI_14 | 57.1 | Neutral |
| MACD Histogram | 0.55 | Bullish |
| vs SMA20 | 1.049x | Above |
| vs SMA50 | 1.047x | Above |
| vs SMA200 | 0.881x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $63.95
- **Stop Loss:** $59.97 (6.2% risk)
- **Target:** $69.92 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 301
- **Position Value:** $19,248.95
- **Portfolio %:** 19.25%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | MOMENTUM (Zone F) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-01-29 (Est: $0.81)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.17 | $1.14 | -2.2% |
| 2025Q2 | $1.75 | $1.60 | -8.7% |
| 2025Q1 | $1.89 | $1.91 | +1.2% |
| 2024Q4 | $1.57 | $1.87 | +18.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*